CervoMed Inc.
CRVO
$4.20
-$0.04-0.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -58.86% | -38.81% | -19.44% | 15.14% | 36.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -58.86% | -38.81% | -19.44% | 15.14% | 36.29% |
| Cost of Revenue | 16.06% | 58.39% | 97.25% | 121.05% | 122.77% |
| Gross Profit | -96.58% | -275.82% | -810.08% | -762.31% | -600.39% |
| SG&A Expenses | 14.37% | 14.77% | 11.02% | 23.22% | 40.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.51% | 41.77% | 58.50% | 77.22% | 86.96% |
| Operating Income | -55.24% | -102.01% | -128.52% | -133.09% | -133.29% |
| Income Before Tax | -65.53% | -114.15% | -348.36% | -349.69% | -650.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.53% | -114.15% | -348.36% | -349.69% | -650.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.53% | -114.15% | -348.36% | -349.69% | -650.10% |
| EBIT | -55.24% | -102.01% | -128.52% | -133.09% | -133.29% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -49.27% | -79.55% | -543.67% | 25.67% | 43.29% |
| Normalized Basic EPS | -49.26% | -79.53% | -543.45% | 25.67% | 43.29% |
| EPS Diluted | -49.27% | -79.55% | -47.46% | 49.33% | 59.03% |
| Normalized Diluted EPS | -49.26% | -79.53% | -437.42% | 27.65% | 44.54% |
| Average Basic Shares Outstanding | 12.01% | 19.32% | 43.40% | 114.02% | 204.13% |
| Average Diluted Shares Outstanding | 12.01% | 19.32% | 40.76% | 108.16% | 191.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |